HLS Therapeutics Inc.
HLS.TOTSXHealthcare● Active
$4.40
$-0.07(-1.57%)
Market Cap$137604280
P/E Ratio—
52W High$5.765
52W Low$0.001
HLS Therapeutics Inc. (HLS.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HLS.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.10
Est. -$0.17 · +41.7%
Revenue
$0.02B
Est. $0.02B · -0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
HLS.TO reports quarterly as a TSX-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.27B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.27B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.11 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.17 | -$0.10 | +41.7% | $0.02B | $0.02B | -0.0% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -$0.04 | -$0.05 | -33.3% | $0.02B | $0.02B | +0.9% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.03 | -$0.17 | -480.0% | $0.02B | $0.02B | +25.2% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.09 | -$0.12 | -38.9% | $0.02B | $0.01B | +33.5% |
| ▼ Q2 FY2025 | May 7, 2025 | -$0.10 | -$0.14 | -40.0% | $0.02B | $0.01B | +43.6% |
| ▲ Q1 FY2025 | Mar 12, 2025 | -$0.18 | -$0.10 | +44.4% | $0.02B | $0.01B | +66.8% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.20 | -$0.15 | +25.0% | $0.02B | $0.02B | -6.6% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.11
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.10
EPS Est.
-$0.17
EPS Surpr.
+41.7%
Revenue
$0.02B
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
-$0.05
EPS Est.
-$0.04
EPS Surpr.
-33.3%
Revenue
$0.02B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.17
EPS Est.
-$0.03
EPS Surpr.
-480.0%
Revenue
$0.02B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.12
EPS Est.
-$0.09
EPS Surpr.
-38.9%
Revenue
$0.02B
Q2 FY2025
May 7, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.10
EPS Surpr.
-40.0%
Revenue
$0.02B
Q1 FY2025
Mar 12, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.18
EPS Surpr.
+44.4%
Revenue
$0.02B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.15
EPS Est.
-$0.20
EPS Surpr.
+25.0%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.02 | $0.02 | $0.02 | 1 |
| Q3 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q1 FY2027 | $-0.04 | $-0.03 | $-0.03 | 1 |
| Q4 FY2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +41.7% | $4.67 | $4.59 | -1.71% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -33.3% | $4.27 | $4.29 | +0.47% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -480.0% | $5.14 | $4.75 | -7.59% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -38.9% | $5.13 | $5.09 | -0.78% |
| ▼ Q2 FY2025 | May 7, 2025 | -40.0% | $4.35 | $4.49 | +3.22% |
| ▲ Q1 FY2025 | Mar 12, 2025 | +44.4% | $3.92 | $4.01 | +2.30% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +25.0% | $3.40 | $3.70 | +8.82% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +0.0% | $3.05 | $3.12 | +2.30% |
Q2 FY2026-1.71%
Report Date
May 15, 2026
EPS Beat/Miss
+41.7%
Price Before
$4.67
Price After
$4.59
Q1 FY2026+0.47%
Report Date
Mar 12, 2026
EPS Beat/Miss
-33.3%
Price Before
$4.27
Price After
$4.29
Q4 FY2025-7.59%
Report Date
Nov 13, 2025
EPS Beat/Miss
-480.0%
Price Before
$5.14
Price After
$4.75
Q3 FY2025-0.78%
Report Date
Aug 14, 2025
EPS Beat/Miss
-38.9%
Price Before
$5.13
Price After
$5.09
Q2 FY2025+3.22%
Report Date
May 7, 2025
EPS Beat/Miss
-40.0%
Price Before
$4.35
Price After
$4.49
Q1 FY2025+2.30%
Report Date
Mar 12, 2025
EPS Beat/Miss
+44.4%
Price Before
$3.92
Price After
$4.01
Q4 FY2024+8.82%
Report Date
Nov 7, 2024
EPS Beat/Miss
+25.0%
Price Before
$3.40
Price After
$3.70
Q3 FY2024+2.30%
Report Date
Aug 8, 2024
EPS Beat/Miss
+0.0%
Price Before
$3.05
Price After
$3.12
Avg Beat Reaction+2.93%
Avg Miss Reaction-1.17%
Beat Rate4 / 8 quarters
Largest Move+8.82% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HLS.TO ends December
HLS Therapeutics Inc. (HLS.TO) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.10 — beating the analyst consensus of $-0.17 by +41.7%. The next HLS.TO earnings date is expected around September 1, 2026.
Each quarter, investors track HLS.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HLS.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HLS.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HLS.TO earnings · 5 questionsHLS Therapeutics Inc.'s next earnings report is expected around September 1, 2026. HLS.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HLS.TO historically reports after market close (AMC).
HLS.TO earnings datewhen is HLS.TO earningsHLS.TO next earnings datewhen does HLS.TO report earningsHLS.TO earnings calendar
▸ Source: FMP · HLS Therapeutics Inc. SEC filings · US GAAP · HLS Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026